Edition:
United Kingdom

People: Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

226.39USD
18 Apr 2019
Change (% chg)

$-0.79 (-0.35%)
Prev Close
$227.18
Open
$227.28
Day's High
$227.80
Day's Low
$221.56
Volume
1,219,471
Avg. Vol
704,725
52-wk High
$388.67
52-wk Low
$216.13

Pangia, Robert 

Mr. Robert W. Pangia is an Independent Director of Biogen Inc. Mr. Pangia served as a director of the Company from 1997 to 2003 during the period the Company was operated as IDEC Pharmaceuticals, and has served as a director since 2003 following IDEC’s merger with Biogen, Inc. Mr. Pangia has been a partner in Ivy Capital Partners, LLC, the general partner of Ivy Healthcare Capital, L.P., a private equity fund specializing in healthcare investments, since 2003. From 2011 to 2016 he was also the Chief Executive Officer of Ivy Sports Medicine, LLC, a medical device company. From October 2007 to October 2009 he also served as the Chief Executive Officer of Highlands Acquisition Corp., a special purpose acquisition company. From 1996 to 2003 Mr. Pangia was self-employed as an investment banker. From 1987 to 1996 he held various senior management positions at PaineWebber, a financial services company, including Executive Vice President and Director of Investment Banking for PaineWebber Incorporated of New York, a member of the Board of Directors of PaineWebber, Inc., Chairman of PaineWebber Properties, Inc. and a member of several of PaineWebber’s executive and operating committees. Mr. Pangia has significant financial acumen and breadth of expertise within the healthcare industry.

Basic Compensation

Total Annual Compensation, USD 151,500
Restricted Stock Award, USD 269,479
Long-Term Incentive Plans, USD --
All Other, USD 61,782
Fiscal Year Total, USD 482,761

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --